SCHEMBL216463

SCHEMBL216463

CC(C)CCCC(C)OCC=O

nearest known ligand 0.37

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.37
PTPN1 P18031 1/20 0.34
BLM P54132 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14952757 0.79 ADH1B (0.46)
SCHEMBL14952747 0.79 ADH1B (0.46)
SCHEMBL215212 0.78 LMNA (0.37) LMNAPTPN1
SCHEMBL2737167 0.78 LMNA (0.37) LMNAPTPN1
SCHEMBL217781 0.78 ALDH1A1 (0.33) LMNA
SCHEMBL216646 0.78 TSHR (0.33) LMNA
SCHEMBL214617 0.78 TSHR (0.33) LMNA
SCHEMBL214596 0.78 TSHR (0.33) LMNA
SCHEMBL12786327 0.77
SCHEMBL215413 0.76 TSHR (0.34) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2594626-B1 Use of oxyacetaldehyde as lily of the valley fragrance SYMRISE AG (DE) 2014-06-25 EP claimed
EP-2594626-A1 Use of oxyacetaldehyde as lily of the valley fragrance Symrise AG (DE) 2013-05-22 EP claimed
EP-2594626-B1 Use of oxyacetaldehyde as lily of the valley fragrance SYMRISE AG (DE) 2014-06-25 EP disclosed
EP-2594626-B1 Use of oxyacetaldehyde as lily of the valley fragrance SYMRISE AG (DE) 2014-06-25 EP disclosed
EP-2594626-A1 Use of oxyacetaldehyde as lily of the valley fragrance Symrise AG (DE) 2013-05-22 EP disclosed
EP-2594626-A1 Use of oxyacetaldehyde as lily of the valley fragrance Symrise AG (DE) 2013-05-22 EP disclosed
US-8088725-B2 Fragrance compositions and compounds GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2012-01-03 US disclosed
US-20100132249-A1 Fragrance Compositions and Compounds GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2010-06-03 US disclosed
EP-2118249-A2 FRAGRANCE COMPOSITIONS AND COMPOUNDS Givaudan Nederland Services B.V. (NL) 2009-11-18 EP disclosed
WO-2008092678-A2 FRAGRANCE COMPOSITIONS AND COMPOUNDS GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2008-08-07 WO disclosed
CN-100375738-C Preparation method of Polyvinyl ether compound IDEMITSU KOSAN CO (JP) 2008-03-19 CN disclosed
CN-100343215-C Polyvinyl ether compound and lubricating oil IDEMITSU KOSAN CO (JP) 2007-10-17 CN disclosed
CN-1234741-C Polyvinyl ether compound and lubricating oil IDEMITSU KOSAN CO (JP) 2006-01-04 CN disclosed
CN-1234737-C Polyvinyl ether compound and lubricating oil IDEMITSU KOSAN CO (JP) 2006-01-04 CN disclosed
CN-1081645-C Polyvinyl ether compound IDEMITSU KOSAN CO (JP) 2002-03-27 CN disclosed
CN-1314419-A Polyvinyl ether compound IDEMITSU KOSAN CO (JP) 2001-09-26 CN disclosed
CN-1233622-A Polyvinyl ether compound and lubricating oil IDEMITSU KOSAN CO (JP) 1999-11-03 CN disclosed
CN-1233621-A Polyvinyl ether compound and lubricating oil IDEMITSU KOSAN CO (JP) 1999-11-03 CN disclosed
CN-1233620-A Polyvinyl ether compound and lubricating oil IDEMITSU KOSAN CO (JP) 1999-11-03 CN disclosed
CN-1080296-A polyvinyl ether compound and lubricating oil IDEMITSU KOSAN CO (JP) 1994-01-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100132249-A1 Fragrance Compositions and Compounds H1-0, H1-10, H1-5 LMNA 2425/4885PTPN1 3871/4885BLM 2352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.